Claims for Patent: 11,559,559

Summary for Patent: 11,559,559

Title:	Angiotensin II alone or in combination for the treatment of hypotension
Abstract:	The present invention relates, inter alia, to a method comprising administering to a subject having high output shock and undergoing treatment with a catecholamine at a dose equivalent to at least about 0.2 mcg/kg/min of norepinephrine a dose of angiotensin II which is effective to raise the blood pressure of the subject to a mean arterial pressure (MAP) of about 65 mm Hg or above, and which is effective to reduce the dose of the catecholamine required to maintain a MAP of about 65 mm Hg to the equivalent of about 0.05-0.2 mcg/kg/min norepinephrine or less, or to the equivalent of about 0.05 mcg/kg/min norepinephrine or less.
Inventor(s):	Lakhmir S. Chawla
Assignee:	George Washington University
Application Number:	US17/380,311
Patent Claims:	1. A method of increasing blood pressure in an adult human patient having distributive shock, comprising: administering Angiotensin II having a sequence of SEQ ID NO:1, or a pharmaceutically acceptable salt thereof, via continuous intravenous infusion at an initial rate of about 20 ng/kg/min; and titrating the rate to 1.25 ng/kg/min to less than 20 ng/kg/min to maintain a mean arterial pressure of about 65 mmHg. 2. The method of claim 1, wherein the Angiotensin II is administered to the adult human patient over a period of about 1 hour to about 7 hours. 3. The method of claim 1, wherein the mean arterial pressure of at least about 65 mmHg is maintained for up to about 6 hours. 4. The method of claim 1, wherein the adult human patient is undergoing treatment with one or more vasopressors at the time that Angiotensin II is first administered. 5. The method of claim 4, wherein the one or more vasopressors is selected from the group consisting of norepinephrine, vasopressin, phenylephrine, epinephrine, and dopamine. 6. The method of claim 1, wherein the Angiotensin II is administered in a parenteral composition comprising water, the Angiotensin II, sodium chloride, and mannitol. 7. The method of claim 1, wherein the distributive shock is septic shock. 8. The method of claim 7, wherein the Angiotensin II is administered to the human patient over a period of about 1 hour to about 7 hours. 9. The method of claim 7, wherein the mean arterial pressure of about 65 mmHg is maintained for up to about 6 hours. 10. The method of claim 7, wherein the human patient is undergoing treatment with one or more vasopressors. 11. The method of claim 10, wherein the one or more vasopressors is selected from the group consisting of norepinephrine, vasopressin, phenylephrine, epinephrine, and dopamine. 12. The method of claim 7, wherein the Angiotensin II is administered in a parenteral composition comprising water, the Angiotensin II, sodium chloride, and mannitol. 13. The method of claim 1, wherein administering the Angiotensin II at an initial rate of about 20 ng/kg/min achieves a mean arterial pressure above about 80 mmHg.